2021
Hepatocellular Carcinoma
Jain A, Mazer B, Deng Y, Ciarleglio M, Jain D, Taddei T, Zhang X. Hepatocellular Carcinoma. American Journal Of Clinical Pathology 2021, 157: 305-313. PMID: 34542582, PMCID: PMC12096300, DOI: 10.1093/ajcp/aqab125.Peer-Reviewed Original ResearchConceptsAnaplastic tumor cellsHepatocellular carcinomaNoncirrhotic liverVascular invasionHistologic patternCirrhotic liverTumor cellsClear cell subtypePathogenesis of HCCHigh histologic gradeLarger tumor sizeHigher tumor stageHigh tumor gradeHigh rateHepatitis BHepatitis CLiver diseaseTumor sizeHistologic gradeTumor stageTumor gradePathologic differencesHCC casesRetrospective analysisPathology archivesCan primary hepatocellular carcinoma histomorphology predict extrahepatic metastasis?
Kumar D, Hafez O, Jain D, Zhang X. Can primary hepatocellular carcinoma histomorphology predict extrahepatic metastasis? Human Pathology 2021, 113: 39-46. PMID: 33905775, DOI: 10.1016/j.humpath.2021.04.008.Peer-Reviewed Original ResearchConceptsMetastatic hepatocellular carcinomaHepatocellular carcinomaHistologic patternHistomorphologic featuresPrimary tumorMetastatic tumorsMacrotrabecular-massive hepatocellular carcinomaCommon histologic patternPathogenesis of metastasisSignificant intratumoral heterogeneityExtrahepatic metastasesLymph nodesMicrovascular invasionAdrenal glandCommon subtypeNoncirrhotic liverCirrhotic liverCommon siteMetastatic tissuesLarge cohortAbdominal cavityHCC subtypesPathology archivesMetastasisHCC metastasis
2017
Immunohistochemical Characterization of the Origins of Metastatic Well-differentiated Neuroendocrine Tumors to the Liver
Yang Z, Klimstra D, Hruban R, Tang L. Immunohistochemical Characterization of the Origins of Metastatic Well-differentiated Neuroendocrine Tumors to the Liver. The American Journal Of Surgical Pathology 2017, 41: 915-922. PMID: 28498280, DOI: 10.1097/pas.0000000000000876.Peer-Reviewed Original ResearchConceptsMetastatic neuroendocrine tumorsWell-differentiated neuroendocrine tumorsMetastatic well-differentiated neuroendocrine tumorNeuroendocrine tumorsPrimary sitePrimary tumorPatient managementPredictive valueExpression of TTF1Potential primary sitesPancreatic neuroendocrine tumorsNegative predictive valuePositive predictive valueSmall intestineStatistically significant associationSite of originMetastatic adenocarcinomaPathology reviewTumor gradeMetastatic neoplasmsLung carcinoidsPathology archivesTissue microarrayStudy cohortImmunohistochemical studiesA Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1
Gaule P, Smithy JW, Toki M, Rehman J, Patell-Socha F, Cougot D, Collin P, Morrill P, Neumeister V, Rimm DL. A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1. JAMA Oncology 2017, 3: 256-259. PMID: 27541827, PMCID: PMC5491359, DOI: 10.1001/jamaoncol.2016.3015.Peer-Reviewed Original ResearchPD-L1 expressionPD-L1Tissue microarrayImmunohistochemical analysisCell death 1 ligand 1PD-1 axis inhibitorsDeath 1 ligand 1Quantitative immunofluorescenceCell linesPredictive diagnostic testsTumor tissue coresPD-L1 proteinPrediction of responseYale Pathology archivesLung cancerClinical utilityPathology archivesDiagnostic testsMonoclonal antibodiesAntibodiesTissue controlsProtein levelsTissue coresLigand 1Concordant results
2012
Microcystic Serous Cystadenoma of the Pancreas With Subtotal Cystic Degeneration
Panarelli N, Park K, Hruban R, Klimstra D. Microcystic Serous Cystadenoma of the Pancreas With Subtotal Cystic Degeneration. The American Journal Of Surgical Pathology 2012, 36: 726-731. PMID: 22498822, DOI: 10.1097/pas.0b013e31824cf879.Peer-Reviewed Original ResearchConceptsMicrocystic serous cystadenomaPancreatic serous cystadenomaSerous cystadenomaPancreatic pseudocystCystic degenerationDifferential diagnosis of pancreatic massesDiagnosis of pancreatic massesPredominant histologic featureBenign cystic neoplasmDegenerative cystic changesMacrocystic serous cystadenomaJohns Hopkins HospitalFibrotic cyst wallTumor volumePancreatic massPathology archivesCystic changesCystic neoplasmsPancreatic neoplasmsCystadenomaDifferential diagnosisHistological featuresMyofibroblast proliferationMultilocular casesRadiographic studies
2006
Quantitative In situ Analysis of β-Catenin Expression in Breast Cancer Shows Decreased Expression Is Associated with Poor Outcome
Dolled-Filhart M, McCabe A, Giltnane J, Cregger M, Camp RL, Rimm DL. Quantitative In situ Analysis of β-Catenin Expression in Breast Cancer Shows Decreased Expression Is Associated with Poor Outcome. Cancer Research 2006, 66: 5487-5494. PMID: 16707478, DOI: 10.1158/0008-5472.can-06-0100.Peer-Reviewed Original ResearchConceptsProgesterone receptorEstrogen receptorPrognostic valueBreast cancerKi-67X-tile softwareProportional hazards modelBreast cancer prognosisBreast cancer showBreast cancer tumorsΒ-catenin expressionYale Pathology archivesHazard ratioNode statusPoor outcomeTumor sizePrognostic markerWorse outcomesImmunohistochemical studyNuclear gradeCase cohortLow-level expressionPathology archivesTissue microarrayBeta-catenin expression
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply